Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.

摘要: The risk of cancer-associated thrombosis can be substantial, depending on tumor type, extent cancer, and type treatment. Unfractionated heparin warfarin have been used in the prevention thrombosis, but low-molecular-weight (LMWH) is widely for venous thromboembolism high-risk patients. Long-term management with associated close monitoring, an increased drug interactions, bleeding. LMWHs may offer alternative outpatient treatment strategy prophylactic because their simpler dosing, more predictable anticoagulant activity, improved safety profile. Clinical trials examining LMWH patients cancer suggest a survival advantage treated groups. Subtle differences pharmacokinetics available exist, each should regarded as distinct drug. Pharmacists aware US Food Drug Administration-approved uses LMWH, dosing options, advantages disadvantages delivery systems various patient populations. play major role educating other health care professionals factor recognition, stratification, proper agent selection thrombosis.